Telix Completes Patient Enrollment in TLX591-Px (Illuccix®) Japan Phase 3 Study
- Written by PR Newswire Asia - Asian Spectator
![]() |
- Completed enrollment of 105 patients in Phase 3 registration study of TLX591-Px (Illuccix®) for prostate cancer imaging in Japan.
- The study data will be used to support a New Drug Application (NDA) for TLX591-Px in Japan.
MELBOURNE, Australia and TOKYO, July 17, 2026 /PRNewswire/ -- Telix Pharmaceuticals (ASX: TLX, NASDAQ: TLX, "Telix") today...





